PTCA Balloon Catheters Market Value Expected to Show $1,431 Million by 2023 : Allied Market Research

"There has been an increased use of drug-eluting balloons in the past few years. The use of drug-eluting balloons has resulted in the reduction in the use of vessel implants (such as stents), which may cause vessel fracture. In addition, drug-eluting balloons are safe and they provide the highest rate of restoration of normal blood flow when compared to other balloon catheters.‐ She further added that ‐reclassification of some of the PTCA catheters by FDA would propel the growth of market as these catheters would come under class II and would not require premarket approval for sale."

According to a new report published by Allied Market Research, titled, PTCA Balloon Catheters Market: Global Opportunity Analysis and Industry Forecast, 2017-2023," the global PTCA balloon catheters market was valued at $1,064 million in 2016, and is expected to reach $1,431 million by 2023, growing at a CAGR of 4.3% from 2017 to 2023.

Send Enquiry on this report @ https://www.alliedmarketresearch.com/purchase-enquiry/2635

Percutaneous transluminal coronary angioplasty (PTCA) is a minimally-invasive procedure used to open blocked or narrowed coronary arteries. PTCA balloons are inflated inside a blocked coronary artery to open up the blockage and allow smooth blood flow. The use of PTCA balloon catheters is on a continuous rise, as it ensures sufficient plaque removal, and optimum patient comfort through a minimally invasive procedure.

Increase in aging population and changes in lifestyle of people, technological advancements, changes in FDA policy, and rise in prevalence of cardiovascular disorders are expected to drive the market growth. However, availability of alternative therapies, and complications associated with PTCA balloon catheters restrain this growth. The upsurge in demand for minimally invasive surgeries, rise in disposable incomes, and growth prospects in emerging economies of Asia-Pacific and LAMEA are expected to provide numerous opportunities for market growth during the forecast period.

The normal balloon catheter segment is expected to maintain its dominant position during the analysis period, owing to reduced complications associated with them when compared to other product types. The drug eluting balloon catheter segment is expected to grow at a rapid CAGR of 4.7% throughout the forecast period.

There has been an increased use of drug-eluting balloons in the past few years. The use of drug-eluting balloons has resulted in the reduction in the use of vessel implants (such as stents), which may cause vessel fracture. In addition, drug-eluting balloons are safe and they provide the highest rate of restoration of normal blood flow when compared to other balloon catheters.

Key Findings of the PTCA Balloon Catheters Market:

• Polyolefin copolymer (POC) accounted for more than half of the materials segment in 2016
• The RX balloon catheter segment accounted for more than four-fifths of the global market in 2016
• Drug eluting balloon catheter is expected to grow at the highest CAGR of 4.7% from 2017 to 2023
• The semi-compliant segment accounted for four-fifths of the global market in 2016
• Asia-Pacific is expected to grow at the highest CAGR of 5.7%, from 2017 to 2023

North America accounted for more than two-fifths of the global market in 2016, and is expected to remain dominant throughout the forecast period. This is attributed to the increase in incidence of cardiovascular diseases; growth in geriatric population; and changing lifestyle of people that leads to cardiac abnormalities. In addition, high adoption rate of technologically advanced devices and presence of highly sophisticated healthcare infrastructure are expected to present new growth opportunities to the players in this market.

Get Access to TOC / Sample Report @ https://www.alliedmarketresearch.com/request-sample/2635

The major companies profiled in the report include The list of key players profiled in this report include Abbott Laboratories, B. Braun Melsungen AG, BIOTRONIK SE & Co. KG, Boston Scientific Corporation, C. R. Bard, Inc., Cardinal Health, Inc., Medtronic plc, MicroPort Scientific Corporation, Terumo Corporation, and THE SPECTRANETICS CORPORATION.

About us

Allied Market Research, a market research and advisory company of Allied Analytics LLP, provides business insights and market research reports to large as well as small & medium enterprises. The company assists its clients to strategize business policies and achieve sustainable growth in their respective market domain.

Allied Market Research provides one stop solution from the beginning of data collection to investment advice. The analysts at Allied Market Research dig out factors that help clients to understand the significance and impact of market dynamics. The company amplies client’s insight on the factors, such as strategies, future estimations, growth or fall forecasting, opportunity analysis, and consumer surveys among others. As follows, the company offers consistent business intelligent support to aid the clients to turn into prominent business firm.

Contact:

David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
Toll Free (USA/Canada):
+1-800-792-5285, +1-503-894-6022, +1-503-446-1141
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1(855)550-5975
help@alliedmarketresearch.com
Web: https://www.alliedmarketresearch.com

This release was published on openPR.